Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors

Precision oncology aims to improve clinical outcome of patients by offering personalized treatment through identifying druggable genomic aberrations within their tumors. This is particularly valid when it comes to offering alternative treatment options for patients with advanced tumors that are chemo-refractory. Patient-derived organoids (PDOs) are 3 dimensional tumoroids that can be expanded ex vivo and are both pheno- and genotypically identical to patients' tumors. Observational studies have shown that PDO-based drug screens can predict treatment response with high sensitivity and specifici

Trial Details

NCT ID
NCT06077591
Phase
NA
Sponsor
Chinese University of Hong Kong
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • Patient-Derived Tumor Organoids
Locations (sample)
  • Hong Kong, N.T., Hong Kong|22.27832,114.17469

Key Eligibility Criteria

  • patients with metastatic, inoperable or advanced solid tumors who are refractory to at least one standard chemo- or targeted drugs.
  • The disease is accessible for a biopsy (radiologic or endoscopic) or resection of a metastatic site.
  • These patients are seen at a multidisciplinary tumor board meeting prior to referrals.
  • aged \>18 years, able to provide written consents to trial participation,

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →